Anzeige
❌
Mehr »
Montag, 16.11.2026 - Börsentäglich über 12.000 News
GBC-Kursziel 2,00 CAD bis Juni 2027, Kurs 0,67 CAD: Verdreifachung drin?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
RB

WKN: A40MF2 | ISIN: US7574683014 | Ticker: 2RH
NASDAQ
16.11.26 | 16:49
0,370 US-Dollar
-5,13 % -0,020
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
REDHILL BIOPHARMA LTD ADR Chart 1 Jahr
5-Tage-Chart
REDHILL BIOPHARMA LTD ADR 5-Tage-Chart

Aktuelle News zur REDHILL BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
02.11.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer4
21.10.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer2
13.10.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer1
02.10.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4-2.849The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO...
► Artikel lesen
REDHILL BIOPHARMA Aktie jetzt für 0€ handeln
30.09.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer2
30.09.RedHill Biopharma Ltd.: RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results574Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota® and Clenpiq®, two established FDA-approved gastrointestinal...
► Artikel lesen
31.08.RedHill Biopharma Divests Talicia Stake to Apotex Subsidiary for $18M12
31.08.RedHill Biopharma divests Talicia to Apotex for $18M upfront8
31.08.RedHill Biopharma Ltd.: RedHill Divests Talicia to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities764Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated...
► Artikel lesen
31.08.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer-
06.08.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer15
28.07.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer14
29.06.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer3
22.06.RedHill Biopharma closes $6 million private placement4
18.06.RedHill Biopharma raises $6M in private placement1
18.06.RedHill Biopharma announces up to $19.4M private placement4
18.06.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer1
09.06.RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation593The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most...
► Artikel lesen
08.06.RedHill Biopharma Ltd. - 6-K, Report of foreign issuer4
03.06.RedHill Biopharma Ltd.: RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak876Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma...
► Artikel lesen
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1